Catheter-directed thrombolysis for acute upper extremity ischemia

J Cardiovasc Surg (Torino). 2015 Jun;56(3):433-9.

Abstract

Aim: Acute nontraumatic upper extremity ischemia has significant chronic disability when not treated adequately and timely. As surgical treatment can be challenging, this study evaluates catheter-directed thrombolysis as first-line treatment for acute upper extremity ischemia.

Methods: Between January 2006 and December 2010, 28 patients (22 women; mean age, 63±16 years) underwent catheter-directed thrombolysis for acute upper extremity ischemia, Rutherford class I or IIa. Proximal extent of the occlusion was in the subclavian (32%), axillary (7%), brachial (25%) and forearm arteries (36%). Median occlusion length was 18 cm (range, 12-43). Causes were embolus (14%), thrombus (39%), thoracic outlet syndrome (14%), paraneoplastic (4%), or unknown (29%).

Results: Technical success was 96%, radiologic success (>95% clot lysis) 61%, and clinical success 68%. Median duration of thrombolysis was 24 hours (range, 18-96). Of the 11 radiologically unsuccessful patients (39%), five were treated conservatively and six underwent surgical intervention. In-hospital amputation-rate was 7%. Four complications occurred: embolization to the lower extremity, a transient ischemic attack, a subcapsular splenic hematoma and a pseudoaneurysm. Cumulative amputation-free survival at six months was 93%, standard error (SE) 4.87 and at one year 88%, SE 6.50.

Conclusion: These results show that catheter-directed thrombolysis is effective in over 60% of patients as first-line treatment of extensive acute upper extremity ischemia and can prevent surgical intervention in these patients.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Amputation, Surgical
  • Catheterization, Peripheral* / adverse effects
  • Disease-Free Survival
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Ischemia / diagnosis
  • Ischemia / drug therapy*
  • Ischemia / physiopathology
  • Limb Salvage
  • Male
  • Middle Aged
  • Netherlands
  • Retrospective Studies
  • Risk Factors
  • Tertiary Care Centers
  • Thrombolytic Therapy / adverse effects
  • Thrombolytic Therapy / methods*
  • Time Factors
  • Treatment Outcome
  • Upper Extremity / blood supply*
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Urokinase-Type Plasminogen Activator / adverse effects
  • Vascular Patency

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator